Cortisol Deficiency in Lenvatinib Treatment of Thyroid Cancer: An Underestimated Common Adverse Event

Background: Lenvatinib treatment has shown a significant improvement in progression-free survival in patients with metastatic, progressive, radioiodine-refractory differentiated thyroid cancer, although its use is associated with considerable toxicity. Fatigue is one of the most frequent adverse eve...

Descripción completa

Detalles Bibliográficos
Autores principales: Monti, Salvatore, Presciuttini, Federica, Deiana, Maria Grazia, Motta, Cecilia, Mori, Fedra, Renzelli, Valerio, Stigliano, Antonio, Toscano, Vincenzo, Pugliese, Giuseppe, Poggi, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2022
Materias:
Thyroid Cancer and Nodules
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792496/
https://www.ncbi.nlm.nih.gov/pubmed/34663079
http://dx.doi.org/10.1089/thy.2021.0040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792496/
https://www.ncbi.nlm.nih.gov/pubmed/34663079
http://dx.doi.org/10.1089/thy.2021.0040

Ejemplares similares